Top Chinese CRO Increases Clinical Trial Productivity and Drives Innovation Across Asia with Medidata Technology

R&G Pharma Studies Co., Ltd. Expands Use of Medidata Cloud Platform
to Streamline Operations in Its Portfolio of Clinical Trials

NEW YORK–(BUSINESS WIRE)–Medidata
(NASDAQ:MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced that R&G
Pharma Studies Co., Ltd.
(“R&G”), a leading contract research
organization (CRO) in China, has broadened its adoption of the Medidata
Clinical Cloud
®, becoming the first Chinese customer to
use Medidata’s clinical trial management technology Medidata
CTMS
®. By leveraging the configurable, cloud-based
system, R&G is optimizing clinical site management and trial activities
for its life sciences customers across the Asia-Pacific (APAC)
region—helping to accelerate innovative drug development and the
delivery of vital new therapies to patients.

“We are pleased that R&G is further realizing the benefits of the
Medidata platform by becoming the first Chinese customer to adopt our
flexible, robust clinical trial management solution,” said Edwin Ng,
Medidata’s vice president of field operations for APeJ (Asia-Pacific
except Japan). “China is a key market in APAC’s expanding clinical trial
landscape, and R&G is well positioned to support clinical innovation in
the region. By pairing Medidata’s agile, cloud-based technology with
R&G’s deep clinical expertise and industry insight, we look forward to
fueling better, more strategic research across the region.”

David Wu, CEO and founder of R&G, said: “R&G is dedicated to providing
high-quality and efficient research services to a wide range of clients
in the life sciences industry, both domestically and abroad. We selected
Medidata CTMS for its simple configurations, which allow us to more
effectively manage complex trial operations across different study
phases and therapeutic areas. With Medidata’s flexible technology, we
can now access and provide our clients with important trial information
in real time—enabling us to meet important milestones on time without
compromising quality.”

Headquartered in Beijing, R&G provides a full range of clinical trial
services—including regulatory affairs, clinical monitoring, data
management capabilities, biostatistics, pharmacoeconomics, site
management organization (SMO) services, and staffing and
outsourcing—supporting studies on both a global and domestic scale. The
company, which offers unique clinical research expertise in areas such
as oncology, cardiovascular, central nervous system and medical devices,
has worked with more than 260 Chinese and international clients and
collaborated with hundreds of sites.

Since early 2015, R&G has been utilizing Medidata’s industry-leading
cloud technology for electronic data capture and management (Medidata
Rave
®). To further streamline R&D operations and
transform its Phase I-IV research programs, R&G is adopting Medidata’s
cloud-based CTMS for its advanced site monitoring capabilities,
high-quality performance reports and real-time insight into trial
activity via its integration with Rave.

“We’re excited to further expand our use of Medidata’s unified
platform, extending beyond Rave to incorporate its robust trial
management and monitoring capabilities—ultimately helping to streamline
workflows for better trial operations and better clinical outcomes,” Wu
added.

Connect with Medidata:

About R&G Pharma Studies

R&G
Pharma Studies
is one of the top contract research organizations
(CRO) in China. The management team consists of experts with
international experience and local expertise, aiming to provide quality
and efficient research services with international standards.

To provide professional, dedicated and efficient full service, R&G has
founded 2 additional subsidiaries—named as IDS and SMS, respectively—and
has a strategic alliance with Winfield Consulting. R&G’s service scope
covers regulatory affairs, clinical monitoring, data management
capabilities, biostatistics, pharmacoeconomics, site management
organization (SMO) services, and staffing and outsourcing. Currently,
R&G has over 600 employees in Asia-Pacific.

About Medidata

Medidata
is the leading global provider of cloud-based solutions for clinical
research in life sciences, transforming clinical development through its
advanced applications and intelligent data analytics. The Medidata
Clinical Cloud® brings new levels of productivity and quality
to the clinical testing of promising medical treatments, from study
design and planning through execution, management and reporting. We are
committed to advancing the competitive and scientific goals of global
customers, which include over 90% of the top 25 global pharmaceutical
companies; innovative biotech, diagnostic and device firms; leading
academic medical centers; and contract research organizations.

Contacts

Medidata Solutions:
Investors:
Hulus
Alpay, +1 212-419-1025
halpay@mdsol.com
or
Media:
Nicole
Pariser, +1 212-659-1069
npariser@mdsol.com
or
Media
– APAC
:
Da Jeong Chong, +82 2-2015-7715
dchong@mdsol.com